article thumbnail

How retailers and “payviders” are disrupting U.S. healthcare in 2024

Clarivate

Strategy #1: innovate and create Amazon founder Jeff Bezos has said that overnight success takes about 10 years — and that ramp-up period may be what’s playing out for the ecommerce giant in healthcare. billion, following an earlier failed healthcare venture with Berkshire Hathaway and JPMorgan Chase.

Retail 52
article thumbnail

H2 2022 to see the decline of Covid-19 vaccines as forecasts decrease

Pharmaceutical Technology

These are forecast to generate $264 billion in sales between 2021 and 2028. Comirnaty, which was first approved in the UK by an Emergency Use Approval (EUA) from the Medicines and Healthcare products Regulatory Agency (MHRA) on December 2, 2020, is currently the leading prophylactic vaccine with 2021 sales of $41.5

Sales 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharma’s reputational high will be short-lived

World of DTC Marketing

A great example of pharma’s profiteering is biosimilar drugs which cost a lot and add billions of dollars to healthcare costs. Pharma has gone to court again and again to delay generic competition of biologic drugs. One company AbbVie has used the courts to stop competition of its top drug Humira.

Pharma 186
article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. They do not have biosimilar or generic competition available in the market.

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. exclusions exist for orphan drug designation and biosimilar competition ).

article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.

article thumbnail

Pharma-biotech partnerships take on new urgency as patent cliffs loom

Clarivate

According to figures from the Healthcare Research & Data Analytics team at Clarivate, the top three best-selling products for Pfizer, AbbVie, Merck/MSD and Bristol Myers Squibb contributed more than half their revenue in 2022, ranging from 53.3% of AbbVie’s $51.8 billion in revenue to a whopping 67.2% for Bristol Myers Squibb’s $44.7

Pharma 52